Status:
COMPLETED
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Melanoma (Skin)
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying samples of tissue in the laboratory from patients receiving carboplatin and paclitaxel with or without sorafenib tosylate may help doctors learn more about the effects of this trea...
Detailed Description
OBJECTIVES: * To independently correlate the gene expression and promoter methylation profiles to chemotherapy response in patients with advanced or metastatic melanoma treated with carboplatin and p...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of melanoma
- Unresectable locally advanced or stage IV disease
- Received carboplatin and paclitaxel with versus without sorafenib on clinical trial ECOG-E2603
- Archived paraffin-embedded tissue samples
- Responder (complete or partial response, or stable disease) and non-responder (disease progression or unavailable)
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
January 19 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 19 2012
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01209299
Start Date
January 19 2012
End Date
February 19 2012
Last Update
May 17 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.